Cediranib (AZD2171)

For research use only. Not for therapeutic Use.

  • CAT Number: I002992
  • CAS Number: 288383-20-0
  • Molecular Formula: C₂₅H₂₇FN₄O₃
  • Molecular Weight: 450.51
  • Purity: ≥95%
Inquiry Now

Cediranib (Cat.No:I002992), also known as AZD2171, is an orally administered, small molecule inhibitor of multiple tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-kit. It has shown potential in inhibiting angiogenesis and tumor growth in preclinical studies. Cediranib has been investigated in clinical trials for the treatment of various types of cancer, including ovarian cancer, non-small cell lung cancer, and breast cancer.


Catalog Number I002992
CAS Number 288383-20-0
Synonyms

AZD2171

Molecular Formula C₂₅H₂₇FN₄O₃
Purity ≥95%
Target Autophagy
Solubility DMSO: ≥ 49 mg/mL
Storage 3 years -20℃ powder
IC50 0.5 nM (VEGFR2); 5 nM/≤3 nM(Flt1/4)
IUPAC Name 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
InChI InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3
InChIKey XXJWYDDUDKYVKI-UHFFFAOYSA-N
SMILES CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5
Reference

<p>
[1]. Wedge SR, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res, 2005, 65(10), 4389-4400. <br />
[2]. Morton CL, et al. Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatr Blood Cancer, 2012, 58(4), 566-571.
</p>

Request a Quote